IsoRay, Inc. (NYSEMKT:ISR)’s shares gained 8.25% to $3.28. The company on Apr. 7 announced the first prostate cancer implant combining IsoRay’s Cesium-131 seeds with C4 Imaging’s Sirius positive signal MRI markers. IsoRay, Inc. (NYSEMKT:ISR) shares after opening at $3.08 moved to $3.10 on last trade day and at the end of the day closed at $2.97. Company price to sales ratio in past twelve months was calculated as 34.86 and price to cash ratio as 36.44. IsoRay, Inc. (NYSEMKT:ISR) showed a positive weekly performance of 12.93%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO) announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support its broad pipeline of immunotherapies and DNA vaccines. He will report to Inovio’s Chief Operating Officer Dr. Niranjan Sardesai. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares fell -5.41% in last trading session and ended the day on $2.80. INO return on equity ratio is recorded as -144.40% and its return on assets is -92.70%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) yearly performance is 418.52 %.
The Spectranetics (NASDAQ:SPNC) shares fell 11.1% during trading on Tuesday after Canaccord Genuity lowered their price target on the stock from $35.00 to $30.00, Analyst Ratings Network.com reports. Canaccord Genuity currently has a buy rating on the stock. The Spectranetics Corporation (NASDAQ:SPNC) shares moved down -11.87% in last trading session and was closed at $23.01 while trading in range of $22.00 – $24.20 – The Spectranetics Corporation (NASDAQ:SPNC) year to date (YTD) performance is -7.96 %.
TherapeuticsMD Inc (NYSEMKT:TXMD) rose 300% since last fall, despite a lack of a legitimate, underlying fundamental reason. TherapeuticsMD Inc (NYSEMKT:TXMD) weekly performance is -23.34%. On last trading day company shares ended up $ 4.63. TherapeuticsMD Inc (NYSEMKT:TXMD) distance from 50-day simple moving average (SMA50) is -29.49%. Analysts mean target price for the company is $8.75.
Leave a Reply